Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420674 | 1.00 | HCRTR2 (0.39) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL13415923 | 0.88 | HCRTR2 (0.40) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL651147 | 0.84 | HCRTR2 (0.38) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL28960535 | 0.84 | HCRTR2 (0.38) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL489371 | 0.83 | NR1H2 (0.39) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL489369 | 0.83 | NR1H2 (0.39) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL1799021 | 0.83 | NR1H2 (0.39) | HCRTR2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL653778 | 0.81 | NR1H2 (0.43) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL1178180 | 0.81 | NR1H2 (0.43) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL8199039 | 0.81 | NR1H2 (0.43) | CHRM2CHRM1CHRM3HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009140448-A1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | AR, ADRA1B, ADRB1 | HCRTR2 1054/4885CHRM2 124/4885CHRM1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.